hydroxyurea
information and resources from the National Cancer Institute
NCI Thesaurus | hydroxyurea
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. NCI Thesaurus | hydroxyurea
A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair.
Hydrea � Bristol-Myers Squibb Dec 07 1967
Hydrea
Decrease need for transfusions in sickle cell anemia
Bristol-Myers Squibb Feb 25 1998
|
|
|
|
news articles
Hydroxyurea Therapy for Infants with Sickle Cell Anemia Mar 31, 2006
AAP Grand Rounds (subscription), Source: Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. ...
CME Questions Mar 31, 2006
AAP Grand Rounds (subscription), ...withdrawn vaccine. Describe the long-term effects of hydroxyurea therapy in children who started treatment in infancy. Discuss the ...
Arsenic Trioxide Effective as Single Agent in Newly Diagnosed APL Mar 31, 2006
Cancer Consultants (press release), As well, 74% of patients received the chemotherapy agent hydroxyurea to help normalize blood cell levels, and eight patients received treatment with a ...
Single-Agent Arsenic Trioxide Very Effective for Treatment of APL Mar 27, 2006
Cancer Consultants (press release), However, 74% of patients received hydroxyurea to lower elevated blood counts, and eight patients also received an anathracycline. ...
Simple Test Could Predict Major Complications in Sickle Cell ... Mar 6, 2006
International News Service, Interestingly, these correlations held whether or not patients were taking hydroxyurea, the standard treatment for the disease, and LDH values were not ...
Icagen Reports Fourth Quarter and Full Year 2005 Financial Results Mar 1, 2006
Genetic Engineering News, ...the largest study of a potential new drug conducted for patients with sickle cell disease since the landmark Multicenter Study of Hydroxyurea conducted in the ...
Icagen Reports Fourth Quarter and Full Year 2005 Financial Results Mar 1, 2006
Finanzen.net, ...study, the largest study of a potential new drugconducted for patients with sickle cell disease since the landmarkMulticenter Study of Hydroxyurea conducted in ...
Blood Test Identifies Sickle Cell Patients at High Mortality Risk Mar 8, 2006
MedPage Today, The test was reliable irrespective of whether patients were taking hydroxyurea, a standard treatment for the disease, or whether they had episodes of vaso ...
Yuet Wai Kan, MD Sickle Cell and Thalassemia Pioneer Feb 28, 2006
Journal of American Medical Association (subscription), Hydroxyurea seems to work in some people, but not primarily by stimulating fetal hemoglobin. We really don't understand exactly how hydroxyurea works yet. ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ... Dec 20, 2005
Cancer Consultants (press release), ...article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus hydroxyurea provides benefit ...
Efficacy of Revlimid in patients with myelofibrosis Dec 13, 2005
Xagena.it, Thirty-six patients ( 88% ) had received prior therapy for myelofibrosis , including thirteen Thalidomide patients ( 32% ), thirteen Hydroxyurea patients ( 32 ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in ... Dec 13, 2005
PR Newswire (press release), Thirty-six patients (88%) had received prior therapy for MF, including thirteen thalidomide patients (32%), thirteen hydroxyurea patients (32%), eleven ...
Dasatinib Therapy for Chronic Myeloid Leukemia Shows Promise ... Dec 15, 2005
DG News ...months. Prior therapy included imatinib in 100% hydroxyurea or anagrelide in 86%, and interferon alpha in 70% of patients. Approximately ...
New Studies Identify Advances In Treatment Of Chronic Myeloid ... Dec 13, 2005
Science Daily (press release) Prior therapy included imatinib in 100 percent hydroxyurea or anagrelide in 86 percent, and interferon alpha in 70 percent of patients. ...
Biomarker May Predict Risk Factor in Sickle Cell Patients ... Dec 13, 2005
DG News Scientists at the National Heart, Lung, and Blood Institute (NHLBI) and investigators affiliated with the Multicenter Study of Hydroxyurea (MSH) Patients ...
|
|
